NCT06827639Not yet recruiting
In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients
In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients.
Source: ClinicalTrials.gov · Last updated 14 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The aim of this study is to describe the tumor microenvironment of solid tumors and to understand the changes induced by anti-cancer treatments, particularly those developed by Innate Pharma. Innate Pharma is a biotechnology company which discovers and develops therapeutic antibodies that exploit the innate immune system to improve cancer treatment. Thanks to this study, it will be possible to correlate clinical and immunological characteristics with the patient\'s clinical features. The analyses generated will contribute to the design and improvement of innovative therapeutic antibodies acting on the immune system
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 640 (estimated)
- First submitted
- 28 Aug 2024
- Start date
- 30 Apr 2025
- Primary completion date
- 30 Apr 2028
- Lead sponsor
- Assistance Publique Hopitaux De Marseille
- Diseases
- Head and neck cancer, Lung cancer, Colorectal cancer, Liver and biliary tract cancer, Gastric and esophageal cancer
- NCT number
- NCT06827639
What you commit to
- Study type: Observational
- Planned participants: 640
- From 30 Apr 2025 to the primary completion date, 30 Apr 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of any investigational agent within 14 days prior first visit;
Other illness
- Patients who are known to be HIV positive
Other
- Patient under guardianship/trusteeship or legally incapacitated person;
- Patient unable to understand read and/or sign an informed consent;
- Uncooperative or potentially non-compliant for the study or study procedures patient, or with foreseeable regular follow-up difficulties;
- Patient without Health insurance scheme or Universal Medical Coverage (CMU) or any equivalent scheme;
Who the study is looking for
- 18 years of age or older
- Histologic, cytologic or imaging confirmation of a malignancy in accordance with targeted indications
- Written informed consent signed from subject prior to performing any protocol-related procedures
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hopital Timone enfants - plateforme d'Immunoprofiling Coordinator of this site? Confirm its status | Marseille | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.